HealthQuill Pharma
Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.
Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.

Read More
US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation of an immunotherapy candidate to treat multiple tumour types.
Drugs Health Pharma

Bristol, BioNTech in $11.1b pact for immunotherapy candidate

HQ Team June 2, 2025: US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation.

Read More
The World Health Organization has called on governments to ban all flavours in tobacco and nicotine products, including cigarettes, pouches, hookahs and e-cigarettes, to protect youth from addiction and disease.
Drugs Health Pharma

WHO urges governments to ban all tobacco flavours, nicotine products

HQ Team June 2, 2025: The World Health Organization has called on governments to ban all flavours in tobacco and nicotine products, including.

Read More
France’s Sanofi SA will acquire US-based Blueprint Medicines Corporation for $9.1 billion to gain access to an immunology medicine for a rare disease and expand the company’s portfolio.
Drugs Health Pharma

Sanofi to acquire Blueprint for $9.1b for immunology medicine

HQ Team June 2, 2025: France’s Sanofi SA will acquire US-based Blueprint Medicines Corporation for $9.1 billion to gain access to an immunology.

Read More
An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the patients with a fatal form of brain cancer.
Drugs Health Pharma

Gilead unit’s experimental therapy shrink brain tumours by 62%

HQ Team June 2, 2025: An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the.

Read More
Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.
Drugs Health Pharma

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

Read More
An investigational oral breast cancer drug being developed by Pfizer and Arvinas Inc. has been shown to delay progression of the disease by three months compared to AstraZeneca’s Faslodex or fulvestrant.
Drugs Health Pharma

Pfizer, Arvinas’ breast cancer test drug scores on disease advance

HQ Team June 1, 2025: An investigational oral breast cancer drug being developed by Pfizer and Arvinas Inc. has been shown to delay.

Read More
The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the late-stage development of a bird flu vaccine for humans.
Drugs Health Pharma

US terminates Moderna contract for investigational bird flu vaccine

HQ Team May 29, 2025: The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the.

Read More
More than one million children are at risk of contracting cholera in war-torn Sudan, where 185 deaths have occurred due to the disease since January.
Drugs Health Pharma

A million children at risk of cholera in conflict-hit Sudan: UNICEF says

HQ Team May 29, 2025: More than one million children are at risk of contracting cholera in war-torn Sudan, where 185 deaths have.

Read More
GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract infections after the study achieved its goal on efficacy.
Drugs Health Pharma

GSK, Sepro end trial for oral drug to treat urinary tract infections

 HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.

Read More